Does Applicability Domain Exist in Microarray-Based Genomic Research? by Shao, Li et al.








1Pharmaceutical Informatics Institute, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China, 2Z-Tech Corporation, an ICF International Company at
the National Center for Toxicological Research/United States Food and Drug Administration, Jefferson, Arkansas, United States of America, 3National Center for
Toxicological Research, United States Food and Drug Administration, Jefferson, Arkansas, United States of America
Abstract
Constructing an accurate predictive model for clinical decision-making on the basis of a relatively small number of tumor
samples with high-dimensional microarray data remains a very challenging problem. The validity of such models has been
seriously questioned due to their failure in clinical validation using independent samples. Besides the statistical issues such
as selection bias, some studies further implied the probable reason was improper sample selection that did not resemble
the genomic space defined by the training population. Assuming that predictions would be more reliable for interpolation
than extrapolation, we set to investigate the impact of applicability domain (AD) on model performance in microarray-
based genomic research by evaluating and comparing model performance for samples with different extrapolation degrees.
We found that the issue of applicability domain may not exist in microarray-based genomic research for clinical applications.
Therefore, it is not practicable to improve model validity based on applicability domain.
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Introduction
Emerging technologies such as gene expression microarrays
offer unprecedented opportunities for clinical cancer research
[1,2,3]. A decade of intensive research into developing predictive
models that are capable of dividing patients into clinically relevant
groups has yielded a number of demonstrable successes. Two
primary examples of this are models to divide patients into groups
with differing event-free survival [4,5,6] and to identify groups of
patients with different expected response to therapy [7,8,9].
However, challenges remain in this field [10,11,12]. The validity
of some models has been questioned due to their failure to clinical
validate usingindependent samples. A recent example is a modelfor
breast cancer prognosis built with two genes by that Reid et al. [11]
that could not be validated by other investigators [13]. From a
statistical point of view, as reviewed by Simon [14], this type of
prediction is a complicated problem and many factors, such as
gene selection rules, sample resubstitution approaches, sample size
concerns, and classification methods are involved. Fortunately,
some of these factors have been extensively investigated and are
incorporated as ‘‘best practices’’ in the research community.
Ambroise, et al. demonstrated that the test/validation set must play
no role in the gene selection process for unbiased prediction results
to be obtained [15]. Ransohoff, et al. [16] emphasized that over-
fitting should be explicitly ruled out by reproducibility assessment
early on, otherwise further research (that is, additional steps in the
validation process) would be unwarranted and wasteful.
The importance of applicability domain (AD) [17] (i.e., the scope
and limitations of a model) has long been discussed and emphasized
in other research fields such as quantitative structure activity
(property) relationship (QSAR) analysis [17,18,19,20]. AD in QSAR
emphasizes that no matter how robust, significant and validated a
model may be, it cannot be expected to reliably predict the modeled
property for the entire universe of chemicals. Therefore, before a
model is put into use for screening chemicals, its domain of
application must be defined and predictions for only those chemicals
that fall in this domain may be considered reliable [17].
However, the AD effect in genomic research has not been fully
understood. The carcinoembryonic antigen (CEA) experience
[21,22] from 40 years ago, where non-reproducible results were
obtained largely due to the variation among the test sets in terms
of the ‘spectrum’ of disease, initially implied the vital importance
of selecting appropriate validation samples in order to reliably
assess the reproducibility of statistical modeling results. Neverthe-
less, this issue has not yet been adequately addressed by the
microarray-based ‘class prediction’ research community until now.
Two sources of divergence between training and validation
samples exist: clinical differences such as diversity in cancer
subtype, drug response, or prognosis, and genomic differences, or
differences between gene expression patterns observed in the
training and validation samples. We have undertaken a compre-
hensive investigation of the role of genomic differences in
predictive model validation to determine if a genomic AD exists
for microarray based ‘class-prediction’ modeling. We hypothesize
that validation samples that more closely resemble the genomic
space defined by the training set might be more likely to have
accurate predictions than validation samples that significantly
diverge from the genomic space defined by the training set.
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introduced to assess the genomic AD issue. Domain extrapolation
is a measurement embedded in the model to place the patients in
different groups according to their extrapolation degree. The role
of genomic AD in microarray-based ‘class-prediction’ will be
tested using three large-scale cancer datasets with six clinical
endpoints [24] contributed to the MAQC Consortium and three
prognostic datasets [4,25,26]. To mimic the real world clinical
situation, each dataset was divided into two sets, i.e., a training and
validation set. We developed the domain extrapolation in the
training set and followed with the assessment of its correlation with
the model’s predictive ability in the validation set. To the best of
our knowledge this is the first attempt to systematically evaluate
the issue of genomic AD in microarray-based genomic research.
Materials and Methods
Datasets
Nine datasets, including three large-scale cancer datasets -
breast cancer (BR) [27], multiple myeloma (MM) [28] and
neuroblastoma (NB) [29] with six clinical endpoints contributed to
the MAQC Consortium [24] and three datasets used in previously
published prognostic modeling research [4,25,26], were selected
and utilized in this study. A concise summary of the datasets is
given in Table 1. More information about these datasets can be
found from the main paper of MAQC phase II [24] and the
original papers [4,25,26].
Briefly, each of the three large-scale cancer datasets has two
endpoints, including the treatment response (BR-pCR and BR-
erpos), the event-free survival (NB-EFS and MM-EFS) and the
overall survival (NB-OS, MM-OS) which are related to cancer
prognosis. The other three datasets are related to the survival of
non-hodgkin lymphoma (NHL), breast cancer (BRC) and
hepatocellular carcinoma (HCC). To simulate the real-world
clinical application of genomic studies, two independent popula-
tions of patients for each dataset created by the MAQC
Consortium or by the original researchers are retained in this
study as the training and validation sets. The sample size for the
training set varies between 33 and 340 and the ratio of positive
events to negative events is from 0.18 to 1.60 while the validation
sets range in size from 19 to 214.
Moreover, two positive (NB-PC, MM-PC) and negative (NB-
NC, MM-NC) control endpoints available from the MAQC
project were also included in this study, which are necessary to
assess the performance of the clinically relevant endpoints against
the theoretical maximum and minimum performance provided by
the controls. The NB-PC and MM-PC were derived from the NB
and MM datasets, respectively, with the endpoints denoted by the
gender while the endpoints for the NB-NC and MM-NC were
generated randomly.
Applicability domain (AD)
AD [30] of a microarray-based predictive model can be stated
as the genomic or biological space, knowledge or information
defined by the training set with which the predictive model has
been developed, and thus for which it is applicable to new patients.
Ideally, the model should only be used to make predictions within
that domain by interpolation not outside that domain by
extrapolation. In this study, we focus exclusively on genomic
AD, or quantifying the degree of extrapolation or difference
between the genomic space defined by the training set and each
validation sample. The genomic AD of a model was defined
based on the Euclidean distance [30] using the method shown as
follows.
Suppose there is a training set (X) that contains n1 samples and p
genes. We can define the mean value (mj) and standard deviation













   2
s
, where xij is the
expression value of gene j for individual xi (i=1,2,...,n1). For any
test set (Y) with n2 samples and p genes, let yij denote the expression
value of the jth gene in ith (i=1, 2,..., n2) sample. Then, the
distance (dij) beyond the training domain for the unknown sample
yij for component j can be calculated by
Table 1. A concise summary of the datasets.
Data Set
code Number of channels (type) Endpoint Description
Endpoint
Code Sample Size Number of events (%)
Training Validation Training Validation
BR 1 (Affymetrix U133A) Treatment Response BR-pCR 130 100 0.34 (33/97) 0.18 (15/85)
BR-erpos 130 100 1.60 (80/50) 1.56 (61/39)
MM 1 (Affymetrix U133Plus2.0) Overall Survival Milestone Outcome MM-OS 340 214 0.18 (51/289) 0.14 (27/187)
Event-free Survival Milestone Outcome MM-EFS 340 214 0.33 (84/256) 0.19 (34/180)
NB 2 (Agilent NB Customized Array) Overall Survival Milestone Outcome NB-OS 246 177 0.32 (59/187) 0.28 (39/138)
Event-free Survival Milestone Outcome NB-EFS 246 193 0.65 (97/149) 0.75 (83/110)
NHL 2 (Lymphochip) Overall Survival Milestone Outcome NHL 160 80 1.22 (88/72) 1.67 (50/30)
BRC 2 (Agilent Hu25K microarrays) 5-year metastasis-free survival BRC 78 19 0.77 (34/44) 1.71 (12/7)
HCC 1 (Affymetrix) 1-year recurrence-free survival HCC 33 27 0.57 (12/21) 0.42 (8/19)
Control 2 (Agilent NB Customized Array) Positive control NB-PC 246 231 1.44 (145/101) 1.36 (133/98)
1 (Affymetrix U133Plus2.0) Positive control MM-PC 340 214 1.33 (194/146) 1.89 (140/74)
2 (Agilent NB Customized Array) Negative control NB-NC 246 253 1.44 (145/101) 1.30 (143/110)
1 (Affymetrix U133Plus2.0) Negative control MM-NC 340 214 1.43 (200/140) 1.33 (122/92)
doi:10.1371/journal.pone.0011055.t001
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Thus, the total percentage of extrapolation di for ith (i=1, 2, ..., n2)
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For each individual yi, di is greater than or equal to 0, with 0
indicating samples lying in domain. The larger di the more distantly
away a sample removed an individual is from the training domain.
For the sake of simplicity, the extrapolation degree di has been
groupedinto four categories: indomain(di=0),lessthan 10% out of
domain (di [ 0–10), 10–20% out of domain (di [ 10–20), and more
than 20% out of domain (di.20).
Statistical analysis
As illustrated in the workflow shown in Figure 1, the analysis
protocol starts on the left side of the graph by developing the best
classifier based on the training set and ends on the right side by
making a prediction about each individual in the validation set,
where the predicted labels and corresponding extrapolation
degrees are recorded in matrices L and D, respectively. To ensure
statistical validity, the procedure was repeated 500 times, resulting
in 500 different classifiers from the training sets and 500
predictions for each individual in the validation sets. Detailed
information about model construction procedures is provided in
Figure S1. In this study, nearest-centroid (NC) [4], k-nearest
neighbor (kNN) [31] and support vector machines (SVM) [32] were
used as classification algorithms.
Based on the 500-run results, we further divided the predictions
in matrix L into subsets according to the category of extrapolation
degrees (i.e., ‘‘in domain’’, ‘‘,10% out of domain’’, ‘‘10–20% out
of domain’’, and ‘‘.20% out of domain’’) deposited in D. The
prediction performance (as measured by Matthews correlation
coefficient (MCC)[33]) for samples in each subset provides an
illustration of model performance versus the stepwise increase of
extrapolation degree. The Matthews Correlation Coefficient
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Where TP is the number of true positives, TN is the number of
true negatives, FP is the number of false positives and FN is the
number of false negatives. MCC varies between 21 and +1 with 0
corresponding to random prediction.
Results
The prediction MCC as a function of extrapolation degree
category for the nine datasets using kNN is shown in Figure 2,
using NC in Figure S2, and using SVM in Figure S3. In each of
the graphs, the red section of the pie-charts representing the data
points show the proportion of the total testing set contained in that
category of extrapolation degree. Generally, no significant impact
on AD is observed, as evidenced by the slight increase in MCC for
samples lying out of domain compared to those in domain for most
datasets except BR-erpos. In BR-erpos validation set, fewer than
2% of the samples were in each of the 10–20% extrapolation and
.20% extrapolation. We re-analyzed the results by distributing
samples into the training and validation sets so that each of these
categories has around 10% of the samples in the validation set.
This modification resulted in the disappearance of any significant
Figure 1. Detailed workflow for the statistical analysis.
doi:10.1371/journal.pone.0011055.g001
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classification algorithms (Figure 3).
In order to accurately assess the upper and lower bounds of
performance and provide a point of reference for the prognostic
datasets, two positive control datasets (i.e., NB-PC and MM-PC)
and two negative control datasets (i.e., NB-NC and MM-NC) were
also investigated. Figure 4 demonstrates the results for these
datasets for each of the three different classification methods used.
The decrease in model performance is nearly negligible for MM-
PC, while model performance drastically deteriorated for NB-PC
when samples lay more than 20% degree out of domain.
Considering that more than 95% of the samples lie in the domain
for NB-PC, the same strategy utilized above was also used to
ensure a larger percentage of samples in each interval, which
yielded significantly smoothed curves shown in Figure 3.
Additionally, negligible variation of model performance is
observed for negative control datasets, where NB-NC and MM-
NC (Figure 4) supports these conclusions.
Discussion
Although differences in genome-wide gene expression patterns has
been suggested previously as a possible reason for some failed
applications of microarray based ‘class-prediction’ models to validate
clinical models [21,22], this is the first comprehensive investigation to
identify whether genomic AD is truly a concern for microarray-based
predictive modeling. Our results strongly suggest that genomic AD
may not exist for clinical microarray-based genomic research. In
other words, the expectation of improving model validity based on
genomic AD is not practical in microarray-based genomic research.
Figure 2. Prediction MCC as a function of extrapolation degree for nine datasets using kNN classifier. The proportion of red in each pie
chart represents the proportion of total validation set samples contained in that extrapolation degree category. Here ‘0’, ‘10’, ‘20’ and ‘.20’ in the X-
axis mean ‘In domain’, ‘0–10% out of domain’, ‘10–20% out of domain’ and ‘more than 20% out of domain’, respectively.
doi:10.1371/journal.pone.0011055.g002
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model performance is beyond the scope of this study. However,
two aspects may provide some explanation to this phenomenon:
first, the genomic AD created by the training set may contain
much more variability than is represented by the signature genes
selected in the predictive models; second, the domain definition
method utilized in this study might not be sensitive enough to
capture the difference between samples inside and outside the
domain. In clinical applications, model AD should be defined in
not only a statistical or genomic but also a biological way,
representing the training domain defined by parameters selected in
statistical models and a priori clinical information. In other words,
the insignificant impact of a genomic AD for complex endpoints
does not negate the importance of considering clinical parameters
when predicting independent validation samples. A simple but
important example is that the information of cancer subtype must
be considered before model development and use to ensure the
reliability of any prediction, since the prognosis may differ
significantly between subtypes [34].
As an interesting side note to this study, the three well known
classification methods, i.e. kNN, NC and SVM, used in this study
(with corresponding results provided in Figure 2 and Figures S2
and S3, respectively) gave very similar prediction performance for
samples with different extrapolation degrees. This offers further
evidence for the lack of significant differences among a large
number of classification methods reported for microarray
applications in terms of the predictive performance[35], a
conclusion also proposed by the newly-finished community-wide
study, MAQC-II [24].
In conclusion, our study found that the applicability domain
may not exist for microarray based clinical genomic research, and
that predictive model performance did not depend on a
measurement of distance between a validation sample and the
training set used to create the model. Because of this, a strategy of
Figure 3. Adjusted prediction MCC versus extrapolation degree for BR-erpos and NB-PC. Three classification algorithms including NC,
kNN and SVM are used, and the percentage of samples in each interval out of domain is adjusted to more than 10%. The proportion of red in each pie
chart represents the proportion of total validation set samples contained in that extrapolation degree category. Here ‘0’, ‘10’, ‘20’ and ‘.20’ in the X-
axis mean ‘In domain’, ‘0–10% out of domain’, ‘10–20% out of domain’ and ‘more than 20% out of domain’, respectively.
doi:10.1371/journal.pone.0011055.g003
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performance is unlikely to be successful. However, the negative
conclusion in this study does not deny the importance of
considering a priori clinical information associated with prognosis
such as cancer subtype and estrogen receptor status for breast
cancer patients before making an individual prediction, the
importance of which has already been proposed by other studies.
Supporting Information
Figure S1 Detailed model construction procedures. The con-
struction of the best classifier is shown as follows (see the
superscripts in this figure): 1. Stratified random sample splitting -
We use the 70/30 splitting, where the 70% samples are for
classifier construction, and the resulting classifier is then used to
predict the 30% samples to obtain the prediction performance of
the classifier. To ensure statistical validity, we repeat this
procedure 500 times, resulting in 500 different classifiers. 2.
Filtering - This step is to generate an initial pool of probesets for
further analysis. Specifically, the original pool of probesets is firstly
sorted by the absolute signal-to-noise (SN) ratio, and then the 200
top ranked probesets are retained for further analysis. 3. Feature
selection - We apply a sequential selection method, with the best
performed probeset being sequentially added into the model to
develop a classifier, which is then evaluated on the 30% samples.
The process is repeated by incrementally adding one probeset at a
time to generate more classifiers. 4. Classifier selection - For
classifier i (i corresponds to the number of probesets selected in the
classifier), if the performance MCC for following five consecutive
classifiers is smaller than or equal to that of classifier i, the process
is stopped and classifier i is selected as the best classifier.
Otherwise, Steps 3 and 4 are repeated. 5. Prediction - Base on
the best classifier, the predicted labels and corresponding
extrapolation degrees for samples in the validation set are
calculated and recorded. Steps 1 to 5 is repeated 500 times,
generating two matrices L(5006p) and D(5006p), which deposit
the predicted labels and corresponding extrapolation degrees,
respectively. Here, p indicates the number of samples in the
validation set.
Found at: doi:10.1371/journal.pone.0011055.s001 (0.29 MB TIF)
Figure S2 Prediction MCC as a function of extrapolation degree
for nine datasets using NC classifier. The proportion of red in each
pie chart represents the proportion of total validation set samples
contained in that extrapolation degree category. Here ‘0’, ‘10’, ‘20’
and ‘.20’ in the X-axis mean ‘In domain’, ‘0–10% out of
domain’, ‘10–20% out of domain’ and ‘more than 20% out of
domain’, respectively.
Figure 4. Prediction MCC versus extrapolation degree for positive and negative control datasets. Three classification algorithms
including NC, kNN and SVM are used. The proportion of red in each pie chart represents the proportion of total validation set samples contained in
that extrapolation degree category. Here ‘0’, ‘10’, ‘20’ and ‘.20’ in the X-axis mean ‘In domain’, ‘0–10% out of domain’, ‘10–20% out of domain’ and
‘more than 20% out of domain’, respectively.
doi:10.1371/journal.pone.0011055.g004
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Figure S3 Prediction MCC as a function of extrapolation degree
for nine datasets using SVM classifier. The proportion of red in
each pie chart represents the proportion of total validation set
samples contained in that extrapolation degree category. Here ‘0’,
‘10’, ‘20’ and ‘.20’ in the X-axis mean ‘In domain’, ‘0–10% out
of domain’, ‘10–20% out of domain’ and ‘more than 20%% out of
domain’, respectively.
Found at: doi:10.1371/journal.pone.0011055.s003 (0.50 MB TIF)
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